Page 33 - 南京医科大学自然版

第44卷第12期 曹 靖，肖志寒，王子辰，等. 超保守癌/睾丸⁃LINC01424表达影响食管鳞癌的进展［J］.
2024年12月 南京医科大学学报（自然科学版），2024，44（12）：1638-1648 ·1647 ·

13（6）：1010-1021 Rev Cancer，2020，20（10）：555-572
［3］ SUNG H，FERLAY J，SIEGEL R L，et al. Global cancer ［15］LIN D C，DINH H Q，XIE J J，et al. Identification of dis⁃
statistics 2020：GLOBOCAN estimates of incidence and tinct mutational patterns and new driver genes in oesopha⁃
mortality worldwide for 36 cancers in 185 countries［J］. geal squamous cell carcinomas and adenocarcinomas［J］.
CA Cancer J Clin，2021，71（3）：209-249 Gut，2018，67（10）：1769-1779
［4］ WONG M C S，HAMILTON W，WHITEMAN D C，et al. ［16］DANESHMAND S. Advanced testis cancer［J］. Eur Urol
Global incidence and mortality of oesophageal cancer and Focus，2019，5（5）：710-712
their correlation with socioeconomic indicators temporal ［17］ HANAHAN D，WEINBERG R A. Hallmarks of cancer：
patterns and trends in 41 countries［J］. Sci Rep，2018，8 the next generation［J］. Cell，2011，144（5）：646-674
（1）：4522 ［18］SINEATH R C，MEHTA A. Preservation of fertility in tes⁃
［5］ MORTENSEN M B. Esophageal cancer：biology，natural tis cancer management［J］. Urol Clin North Am，2019，46
history，staging and therapeutic options［J］. Minerva Med， （3）：341-351
2007，98（4）：299-303 ［19］ZHANG Y J，ZHANG Y X，ZHANG L. Expression of can⁃
［6］ ALLEMANI C，MATSUDA T，DI CARLO V，et al. Global cer ⁃ testis antigens in esophageal cancer and their prog⁃
surveillance of trends in cancer survival 2000⁃14（CON⁃ ress in immunotherapy［J］. J Cancer Res Clin Oncol，
CORD⁃3）：analysis of individual records for 37 513 025 2019，145（2）：281-291
patients diagnosed with one of 18 cancers from 322 popu⁃ ［20］WANG C，GU Y Y，ZHANG K，et al. Systematic identifi⁃
lation⁃based registries in 71 countries［J］. Lancet，2018， cation of genes with a cancer⁃testis expression pattern in
391（10125）：1023-1075 19 cancer types［J］. Nat Commun，2016，7：10499
［7］ RILEY R S，JUNE C H，LANGER R，et al. Delivery tech⁃ ［21］SHORT M W，BURGERS K G，FRY V T. Esophageal can⁃
nologies for cancer immunotherapy［J］. Nat Rev Drug Dis⁃ cer［J］. Am Fam Physician，2017，95（1）：22-28
cov，2019，18（3）：175-196 ［22］MENG X，ZHENG A P，WANG J，et al. Nimotuzumab
［8］ MIMURA K，YAMADA L，UJIIE D，et al. Immunotherapy plus concurrent chemo⁃radiotherapy in unresectable locally
for esophageal squamous cell carcinoma：a review［J］. Fu⁃ advanced oesophageal squamous cell carcinoma（ESCC）：
kushima J Med Sci，2018，64（2）：46-53 interim analysis from a phase 3 clinical trial［J］. Br J Can⁃
［9］ KUO H Y，GUO J C，HSU C H. Anti⁃PD⁃1 immunothera⁃ cer，2023，129（11）：1787-1792
py in advanced esophageal squamous cell carcinoma：a ［23］WANG J F，ZHAO Q，CAI L，et al. Efficacy of bevacizumab
long ⁃ awaited breakthrough finally arrives［J］. J Formos and gemcitabine in combination with cisplatin in the treat⁃
Med Assoc，2020，119（2）：565-568 ment of esophageal cancer and the effect on the incidence
［10］JING W，YAN W W，LIU Y G，et al. Slight advantages of of adverse reactions［J］. Biomed Res Int，2022，2022：
nimotuzumab versus cetuximab plus concurrent chemora⁃ 2317181
diotherapy in locally advanced esophageal squamous cell ［24］ MAKINO T，NAKAI S，MOMOSE K，et al. Efficacy and
carcinoma［J］. Cancer Biol Ther，2019，20（8）：1121- survival of nivolumab treatment for recurrent/unresectable
1126 esophageal squamous⁃cell carcinoma：real⁃world clinical
［11］BANDO H，KOTANI D，TSUSHIMA T，et al. TENERGY： data from a large multi⁃institutional cohort［J］. Esophagus，
multicenter phase Ⅱ study of atezolizumab monotherapy 2024，21（3）：319-327
following definitive chemoradiotherapy with 5 ⁃ FU plus ［25］ XU T P，BAI J N，ZHAO K，et al. Induction therapy of
cisplatin in patients with unresectable locally advanced tislelizumab combined with cisplatin and 5 ⁃ fluorouracil
esophageal squamous cell carcinoma［J］. BMC Cancer， and subsequent conversion surgery in patients with unre⁃
2020，20（1）：336 sectable advanced esophageal squamous cell carcinoma：
［12］ AI H H，YANG H，LI L，et al. Cancer/testis antigens： a phase 2，single center study［J］. Ann Surg Oncol，2024：
promising immunotherapy targets for digestive tract can⁃ 31（13）：9321-9331
cers［J］. Front Immunol，2023，14：1190883 ［26］LUO H Y，LU J，BAI Y X，et al. Effect of camrelizumab
［13］GHAFOURI⁃FARD S，MODARRESSI M H. Cancer⁃testis vs. placebo added to chemotherapy on survival and pro⁃
antigens：potential targets for cancer immunotherapy［J］. gression⁃free survival in patients with advanced or meta⁃
Arch Iran Med，2009，12（4）：395-404 static esophageal squamous cell carcinoma：the ESCORT⁃
［14］MARTÍNEZ⁃JIMÉNEZ F，MUIÑOS F，SENTÍS I，et al. A 1st randomized clinical trial［J］. JAMA，2021，326（10）：
compendium of mutational cancer driver genes［J］. Nat 916-925